Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Zypol is a pharmaceutical product containing 500 mg of paracetamol (acetaminophen), a small molecule analgesic and antipyretic. Developed and manufactured by Unimed Healthcare, a South African generic pharmaceutical company, Zypol is indicated for the treatment of mild to moderate pain and inflammation, as well as symptoms associated with the common cold and influenza. It functions primarily by inhibiting prostaglandin synthesis within the central nervous system, which elevates the pain threshold and reduces fever. The medication is available as an over-the-counter (OTC) oral tablet, characterized as a flat, round, green tablet with a break line.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Zypol.